Week Ending March 21, 2022

FDA Approves FoundationOne CDx to Identify EGFR Therapeutics for Certain Patients With NSCLC
“FoundationOne CDx has been approved as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 alternations eligible for treatment with EGFR tyrosine kinase inhibitors.”

Hollings Cancer Center and newly formed Southeastern Consortium for Lung Cancer Health Equity awarded $3 Million Stand Up To Cancer grant
“MUSC Hollings Cancer Center received its first Stand Up To Cancer (SU2C) grant that will make it part of the Southeastern Consortium for Lung Cancer Health Equity (SC3), a group that will focus on why lung cancer continues to be one of the leading causes of death among racially and ethnically diverse populations in the nation.”

Barriers to Access for COVID-19 Treatments Put Patients With Cancer at Risk
“Amid the surge of the omicron variant, the FDA issued an emergency use authorization for the orally administered antiviral combination, which can reduce the rate hospitalization or death by 87% compared with no treatment.”

Examining the Potential of CAR-T Cell Therapy in Lung Cancer
“In a new review published in Thoracic Cancer, researchers outlined common tumor-associated antigens (TAA) in clinical trials of chimeric antigen receptor-modified T (CAR-T) cell therapy for lung cancer to help identify new approaches to pre-clinical experiments and clinical trials for this patient population.”

Merck’s Keytruda Delivers Reduced Risk of Death in Adjuvant NSCLC
“Merck announced that its proposed treatment Keytruda for non-small cell lung cancer delivered positive results from its Phase III trial.”

New Data Emerge from KEYNOTE-091 Regarding Adjuvant Pembrolizumab in Early NSCLC
“Updated findings from the pivotal phase 3 KEYNOTE-091 trial (also known as the PEARLS trial; NCT02504372) of pembrolizumab (Keytruda) as adjuvant treatment for patients with stage IB to IIIA non–small cell lung cancer (NSCLC) showed superior disease-free survival (DFS) outcomes with active therapy vs placebo.”

ES-IMRT Reduces Esophagitis in Non-Small Cell Lung Cancer
“Esophageal-sparing intensity-modulated radiotherapy (ES-IMRT) significantly reduced esophagitis but did not improve esophageal quality of life (QOL) in patients with advanced non-small cell lung cancer (NSCLC), according to research published in JAMA Oncology.”

New Class of Oncogenic Fusions Revealed in Lung and Pancreatic Cancer
“A Yale Cancer Center research team has identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development. The research is described online ahead of print in Clinical Cancer Research.”

Dr. Socinski on Treatment Considerations for Difficult-to-Treat Patients in Lung Cancer
“Mark A. Socinski, MD, executive director, Thoracic Center, medical oncologist, AdventHealth Cancer Institute, discusses therapeutic considerations for difficult-to-treat patients in lung cancer.”